Fusion Pharmaceuticals' filing for a shelf offering of up to 4.8 million common shares by selling stockholders may impact its stock price. The offering could lead to an increase in the number of shares available in the market, which may affect the stock price. However, the short-term impact is uncertain as it depends on the market's reaction to the news and the actual number of shares sold.